TY - JOUR
T1 - Anti-adhesion molecule therapies in inflammatory bowel disease
T2 - Touch and go
AU - Stefanelli, Tommaso
AU - Malesci, Alberto
AU - De La Rue, Sarah A.
AU - Danese, Silvio
PY - 2008/5
Y1 - 2008/5
N2 - Exploration of the mechanisms underlying the inflammatory bowel diseases [N. Mori, Y. Horie, M.E. Gerritsen, D.C. Anderson, D.N. Granger, Anti-inflammatory drugs and endothelial cell adhesion molecule expression in murine vascular beds. Gut 1999;44:186-95] is a leading field of medical research that drives the application of biological therapies to human diseases. Indeed, many inflammatory mediators can be targeted in the gut by monoclonal antibodies. A recent direction for these therapeutics is targeting of the adhesion molecule family. This molecule family mediates the adhesion and extravasation of leukocytes through the endothelium at sites of inflammation. This is a complex multistep process that has been extensively investigated in recent years; thanks to these studies some adhesion molecules have been identified to specifically mediate leukocyte migration to gut inflammatory sites, like α4β7 integrin. This review outlines the scientific basis behind this therapeutic approach, and describes the principal clinical studies that have been carried out on these new molecules in patients with IBD.
AB - Exploration of the mechanisms underlying the inflammatory bowel diseases [N. Mori, Y. Horie, M.E. Gerritsen, D.C. Anderson, D.N. Granger, Anti-inflammatory drugs and endothelial cell adhesion molecule expression in murine vascular beds. Gut 1999;44:186-95] is a leading field of medical research that drives the application of biological therapies to human diseases. Indeed, many inflammatory mediators can be targeted in the gut by monoclonal antibodies. A recent direction for these therapeutics is targeting of the adhesion molecule family. This molecule family mediates the adhesion and extravasation of leukocytes through the endothelium at sites of inflammation. This is a complex multistep process that has been extensively investigated in recent years; thanks to these studies some adhesion molecules have been identified to specifically mediate leukocyte migration to gut inflammatory sites, like α4β7 integrin. This review outlines the scientific basis behind this therapeutic approach, and describes the principal clinical studies that have been carried out on these new molecules in patients with IBD.
KW - Anti αβ integrin therapy
KW - Cell adhesion molecules
KW - Crohn's Disease
KW - Ulcerative Colitis
UR - http://www.scopus.com/inward/record.url?scp=43449095992&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43449095992&partnerID=8YFLogxK
U2 - 10.1016/j.autrev.2008.01.002
DO - 10.1016/j.autrev.2008.01.002
M3 - Article
C2 - 18486923
AN - SCOPUS:43449095992
VL - 7
SP - 364
EP - 369
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
SN - 1568-9972
IS - 5
ER -